U.S. Food and Drug Administration building

Manufacturers of popular GLP-1 weight-loss drugs are struggling to keep up with unprecedented demand. Wegovy from Novo Nordisk and Zepbound from Eli Lilly & Co. are in tight supply and may be hard to obtain for the next several months..

The U.S. Food and Drug Administration updated its drug shortage database in April to reflect that most doses of Zepbound have limited availability because of "demand increase for the drug." Patients typically start at the lowest dose and work their way up to higher doses. Currently, only the lowest dose is readily available

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Employee Participation
Employee-Paid
Employer-Paid